Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12071533

Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.

M Nishi·T Takeda·Y Hatae·J Hanai·K Fujita·H Ichimiya·T Tanaka
View original source ↗Export metadata ↓

Abstract

The aim of this study is the estimation of the contribution of HPLC mass screening for neuroblastoma to the decrease in deaths due to this disease. The mortality rates of malignant neoplasms of the adrenal glands (ICD 9, 1940; ICD 10, C74; virtually all the cases of these codes are neuroblastoma during childhood) at 1-4 years of age in cohorts born in 1979-1984, 1985-1988, and 1989-1992 in the whole of Japan were calculated, using data obtained from the Ministry of Health and Welfare. The numbers of infants screened by HPLC in the cohorts were estimated through the reports of the Ministry of Health and Welfare and the database of the Japanese Society for Mass-screening. The mortality of the cohort born in 1989-1992, in which 77.8% of the live births were screened by HPLC, was 1.73 per 100,000 live births. This is about half of that (3.26) of the cohort born in 1979-1984, in which few infants were screened. On the assumption that cases of the 1985-1988 and 1989-1992 cohorts died according to the mortality rate of the 1979-1984 cohort, the expected numbers of deaths were estimated; that for the 1985-1988 cohort was 178.51 (of them, that for the infants screened by HPLC was 39.65), and that for the 1989-1992 cohort was 159.78 (of them, that for the infants screened by HPLC was 124.33). The observed numbers of deaths were 145 and 85, respectively. Assuming that non-HPLC methods have no effects and using 2 unknown quantities x (contribution of HPLC) and y (other factors), simultaneous equations (1) 178.51 - 39.65x - 178.51y = 145 and (2) 159.78 - 124.33x - 159.78y = 85 were made. Solving them, x = 0.5041 and y = 0.0757 were obtained. In conclusion HPLC screening targeting infants aged 6 months reduces death of adrenal neuroblastomas at 1-4 years of age by about 50%.

Explore related subjects

Adrenal Gland NeoplasmsChildChild, PreschoolChromatography, High Pressure LiquidCohort StudiesFemaleHumansIncidenceInfantInfant, NewbornJapanMaleMass ScreeningNeuroblastomaSurvival RateComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Nishi, T Takeda, Y Hatae, J Hanai, K Fujita, H Ichimiya, T Tanaka. 2002. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.. https://pubmed.ncbi.nlm.nih.gov/12071533/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Pheochromocytoma: the expanding genetic differential diagnosis.

Pheochromocytomas and paragangliomas are tumors of the autonomic nervous system; pheochromocytomas are tumors of the adrenal medulla, and paragangliomas are extra-adrenal tumors arising from either the sympathetic nervous system or parasympathetic ganglia. It has previously been estimated that approximately 10%-15% of pheochromocytomas are due to hereditary causes. However, our increased understanding of the three hereditary syndromes (neurofibromatosis 1, multiple endocrine neoplasia type 2, and von Hippel-Lindau syndrome) in which pheochromocytoma is found and the recent discovery that mutations in genes in the succinate dehydrogenase family (SDHB and SDHD) predispose to pheochromocytoma have necessitated a re-evaluation of the genetic basis of pheochromocytoma. These studies indicate that the frequency of germline mutations associated with isolated pheochromocytoma is higher than previously estimated, with both hospital-based series and a large population-based series indicating that the frequency of germline mutations in RET, VHL, SDHB, and SDHD taken together approximates 20%. In all patients with pheochromocytoma, including those with known hereditary syndrome or a positive family history, the frequency of germline mutations in these four genes together approaches 30%. Given the frequency of germline mutations, consideration should be given to genetic counseling for all patients with pheochromocytoma and is particularly important for individuals with a positive family history, multifocal disease, or a diagnosis before age 50. Identification of patients with hereditary pheochromocytoma is important because it can guide medical management in mutation-positive patients and their families. This review provides an overview of the known genetic syndromes that are commonly associated with pheochromocytoma, examines recent data on the association of germline mutations in the succinate dehydrogenase gene family with pheochromocytoma, and suggests guidelines for the genetic evaluation of pheochromocytoma patients.

Adrenal Gland Neoplasms↗
PubMed2003

[Expression of urotensin II mRNA in normal adrenal medulla and pheochromocytoma tissues].

OBJECTIVE: To investigate the expression of human urotensin II (UII) mRNA in normal adrenal medulla and pheochromocytoma tissues. METHODS: The total RNA of normal adrenal medulla from 9 males who died of accidents and the total RNA of pheochromocytoma tissues resected from 19 patients were extracted. The expression of UII mRNA was studied by reverse transcription-polymerase chain reaction (RT-PCR). UII and its internal control GAPDH were co-amplified in the same tube. Semi-quantitative analysis of the mRNA expression level of UII was carried out based on the ratios of the grey scale of the amplified target band to that of the control band (UII/GAPDH). RESULTS: The amplified product of UII is a 385 bp fragment and 99.7% of the bases were the same as the sequence registered in the GenBank. The UII/GAPDH in the normal adrenal medullae and pheochromocytomas were 0.69 +/- 0.29 (n = 9) and 0.22 +/- 0.18 (n = 19) respectively (P < 0.05). CONCLUSION: Both the normal adrenal medulla and pheochromocytoma express UII mRNA. The expression of UII mRNA is lower in pheochromocytoma than in normal adrenal medulla.

Adrenal Gland Neoplasms↗
PubMed2003

Transition from open to laparoscopic adrenalectomy: the need for advanced training.

BACKGROUND: We sought to determine the learning curve for laparoscopic adrenalectomy (LA), current use of the procedure, and if indications for adrenalectomy had changed in the past decade. METHODS: A retrospective chart review was performed for all adrenalectomies after 1990. Practicing community surgeons in Oregon were mailed a questionnaire. RESULTS: Seventy-five LAs were performed at the Oregon Health and Sciences University and Portland VA Medical Center. Average operating room (OR) time was 161 min and average estimated blood loss (EBL) was 84 ml. There were four complications and two conversions. Comparing the first 20 to the last 20 patients, OR times were 154 vs 159 min (not significant), and EBL was 102 vs 47 ml ( p < 0.05). There were two vs one complications ( p > 0.05) and one conversion each. Most residents completed less than two procedures during training, and community surgeons performed none during training. Of 17 currently performing LA, 14 had postresidency training. Open technique was used more often for hormonal ablation and malignancy. CONCLUSION: Operative time and complications do not decrease with experience, but EBL does. Few, if any, residents acquire enough experience to perform LA in practice. The procedure is performed laparoscopically more often for benign disease.

Adrenal Gland Neoplasms↗